A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients

Bai, Yang; Zhan, Yunbo; Yu, Bin; Wang, Weiwei; Wang, Li; Zhou, Jingxin; Chen, Ruo-kun; Zhang, Fengjiang; Zhao, Xiaofeng; Duan, Wenchao; Wang, Yanmin; Liu, Jun; Bao, Ji; Zhang, Zhenyu; Liu, Xianzhi

doi:10.1159/000492317

Cited by 35 publications

(29 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The gene is located on chromosome 5, and it is reported to be highly expressed specifically in the brain, with higher expression in different parts of the Central Nervous System (CNS), including middle temporal gyrus, cerebellum and frontal cortex 35 . The gene is associated with several neuropsychiatric disorders, as well as glioma, the most common CNV tumor among adults 36 . Looking at glioma cells, and through in vitro and in vivo functional experiments, Bai et al 36 showed that CDH18 acts as a tumor suppressor through the downstream gene target UQCRC2, and suggested targeting CDH18 in glioma treatmen.…”

Section: Discussionmentioning

confidence: 99%

“…The gene is associated with several neuropsychiatric disorders, as well as glioma, the most common CNV tumor among adults 36 . Looking at glioma cells, and through in vitro and in vivo functional experiments, Bai et al 36 showed that CDH18 acts as a tumor suppressor through the downstream gene target UQCRC2, and suggested targeting CDH18 in glioma treatmen. Moreover, CDH18 was reported in a meta-analysis of depression personality trait association as the nearest gene to rs349475 37 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Genome-Wide Association Study of Brain Connectivity Changes for Alzheimer’s Disease

Elsheikh

Chimusa

Mulder

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Genome-Wide Association Study of Brain Connectivity Changes for Alzheimer’s Disease

Elsheikh

Chimusa

Mulder

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Recently, JAZF1 was found to control the biological behaviours of many tumors as endometrial sarcomas and cancer prostate, and it was considered a tumor suppressor (Hodge et al, 2016, Hazelett et al, 2014. Tumor suppressors have participated in many biological cellular activities as cell proliferation, apoptosis and control of cell cycle (Pospiechet al, 2018, Qiu et al, 2018, Nikbakht et al, 2018, Bai et al, 2018.…”

Section: Discussionmentioning

confidence: 99%

TFAP2B, AP-1 and JAZF1 Expression in Tissues of Papillary Thyroid Carcinoma Patients; Clinical, Pathological and Prognostic Values

Abuderman

Harb

Gertallah

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: Transcription factor activating protein 2 B (TFAP2 B) is a transcription factor that regulates many steps of embryogenesis, cell growth, apoptosis and recently oncogenesis and cancer progression. AP-1 is a transcription factor that is a downstream molecule of the MAPK signaling pathway. Juxtaposed with zinc finger gene 1 (JAZF1) is a recently detected transforming growth factor which has a role in carcinogenesis. Hence the present study aimed to assess those markers expression in tissues from patients with such cancer correlation their expression with clinic-pathological findings of the tumor and prognostic and follow-up findings of patients. Methods: We have collected tissue samples from papillary thyroid cancer patients and adjacent non-neoplastic tissues from 80 patients. We assessed the expression of TFAP2B, AP-1 and JAZF1 using immunohistochemistry. Results: Expression of TFAP2B was positively associated with lymph nodes metastases (p=0.003), distant metastases (p=0.002), recurrence of the tumor (p=0.002), unfavourable disease-free survival rate (p=0.003). AP-1 expression is positively associated with advanced stage (p=0.002), presence of extra-thyroid invasion (p=0.005), recurrence of the tumor (p=0.005), unfavorable disease-free survival rate (p=0.01). JAZF1 expression is negatively associated with huge tumor size (0.023), vascular invasion (p=0.007) and unfavorable overall survival rate (p=.030). Conclusion: High expression levels of TFAP2B and AP-1 and low expression levels of JAZF1 were associated with unfavourable pathological, prognostic parameters and dismal patient's outcome.

show abstract

“…The gene is located on chromosome 5, and it is reported to be highly expressed specifically in the brain, with higher expression in different parts of the Central Nervous System (CNS), including middle temporal gyrus, cerebellum and frontal cortex 24 . The gene is associated with several neuropsychiatric disorders, as well as glioma, the most common CNV tumor among adults 25 . Looking at glioma cells, and through in vitro and in vivo functional experiments, 25 et al showed that CDH18 act as a tumor suppressor through the downstream gene target UQCRC2, and they suggested targeting CDH18 in the gliomas treatment discovery.…”

Section: Discussionmentioning

confidence: 99%

“…The gene is associated with several neuropsychiatric disorders, as well as glioma, the most common CNV tumor among adults 25 . Looking at glioma cells, and through in vitro and in vivo functional experiments, 25 et al showed that CDH18 act as a tumor suppressor through the downstream gene target UQCRC2, and they suggested targeting CDH18 in the gliomas treatment discovery. Moreover, CDH18 was reported in a meta-analysis of depression personality trait association as the nearest gene to rs349475 26 .…”

Section: Discussionmentioning

confidence: 99%

Genome-Wide Association Study of Brain Connectivity Changes for Alzheimer’s Disease

Elsheikh¹,

Chimusa²,

Mulder³

et al. 2018

Preprint

View full text Add to dashboard Cite

Variations in the human genome have been found to be an essential factor that affects susceptibility to Alzheimer’s disease. Genome-wide association studies (GWAS) have identified genetic loci that significantly contribute to the risk of Alzheimers. The availability of genetic data, coupled with brain imaging technologies have opened the door for further discoveries, by using data integration methodologies and new study designs. Although methods have been proposed for integrating image characteristics and genetic information for studying Alzheimers, the measurement of disease is often taken at a single time point, therefore, not allowing the disease progression to be taken into consideration. In longitudinal settings, we analyzed neuroimaging and single nucleotide polymorphism datasets obtained from the Alzheimer’s Disease Neuroimaging Initiative for three clinical stages of the disease, including healthy control, early mild cognitive impairment and Alzheimer’s disease subjects. We conducted a GWAS regressing the absolute change of global connectivity metrics on the genetic variants, and used the GWAS summary statistics to compute the gene and pathway scores. We observed significant associations between the change in structural brain connectivity defined by tractography and genes, which have previously been reported to biologically manipulate the risk and progression of certain neurodegenerative disorders, including Alzheimer’s disease.

show abstract

A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients

Cited by 35 publications

References 40 publications

Genome-Wide Association Study of Brain Connectivity Changes for Alzheimer’s Disease

Genome-Wide Association Study of Brain Connectivity Changes for Alzheimer’s Disease

TFAP2B, AP-1 and JAZF1 Expression in Tissues of Papillary Thyroid Carcinoma Patients; Clinical, Pathological and Prognostic Values

Genome-Wide Association Study of Brain Connectivity Changes for Alzheimer’s Disease

Contact Info

Product

Resources

About